Associate Director Market Access, HTA & Pricing

At Genmab, we are dedicated to building extra[not]ordinary® futures, together, by developing antibody products and groundbreaking, knock-your-socks-off KYSO antibody medicines® that change lives and the future of cancer treatment and serious diseases. We strive to create, champion and maintain a global workplace where individuals’ unique contributions are valued and drive innovative solutions to meet the needs of our patients, care partners, families and employees.

Our people are compassionate, candid, and purposeful, and our business is innovative and rooted in science. We believe that being proudly authentic and determined to be our best is essential to fulfilling our purpose. Yes, our work is incredibly serious and impactful, but we have big ambitions, bring a ton of care to pursuing them, and have a lot of fun while doing so.

Does this inspire you and feel like a fit? Then we would love to have you join us!

The Role

Help shape market access within Genmab’s developing UK oncology affiliate. The Associate Director will lead UK access plans and own end-to-end development and delivery of HTA submissions for assigned assets and indications, supporting timely and equitable patient access.

Working closely with the Head of Market Access and Pricing, the role combines deep clinical and health economic understanding with UK payer expertise to develop scientifically defensible reimbursement submissions and informed pricing recommendations. It offers substantial ownership, direct engagement with UK decision-makers and the opportunity to influence regional and global evidence plans.

Key responsibilities

UK access strategy and launch planning

• Develop and deliver market access and HTA strategies for assigned oncology assets, aligned with UK portfolio priorities and global strategy.
• Lead market access contributions within UK launch and brand teams, translating payer requirements and NHS insights into clear priorities and practical access plans.
• Identify reimbursement barriers and contribute UK access perspectives to pipeline planning, evidence generation and lifecycle management.

HTA submission ownership and delivery

• Own end-to-end planning, development and delivery of NICE and other relevant UK HTA submissions, from scoping through appraisal and final guidance.
• Lead development of the integrated UK dossier and reimbursement case, bringing together clinical evidence, economic analyses and NHS insights.
• Lead cross-functional submission teams and external agencies, managing agreed budgets, deliverables and timelines.
• Lead engagement with HTA bodies for assigned appraisals, including clarification responses, consultation submissions and committee preparation.
• Coordinate required scientific and business reviews and approvals, ensuring material issues are resolved or escalated before submission.

HTA evidence assessment and value demonstration

• Critically evaluate survival analyses and extrapolations, considering data maturity, statistical fit, clinical plausibility and external validation.
• Interrogate economic model structures and assumptions, including treatment-effect duration, subsequent therapies, utilities, costs and uncertainty.
• Assess comparative evidence, including indirect treatment comparisons, and its implications for the UK reimbursement case.
• Work with evidence specialists to develop and justify proposed UK base-case assumptions, scenario analyses and responses to appraisal challenges.
• Define UK evidence requirements and agree supporting deliverables and timelines with regional and global colleagues.
• Lead preparation of integrated responses to clinical and economic appraisal questions, drawing on specialist contributors to explain and defend the evidence.

Pricing, reimbursement and NHS access

• Develop pricing…